Abstract 1443P
Background
Hypertension is a common adverse drug reaction of using angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as bevacizumab or ramucirumab. Moreover, angiogenesis inhibitor-induced hypertension is associated with improved clinical outcomes in various cancers. Here, we retrospectively analyzed these data from FRUTIGA to evaluate whether clinical outcomes were associated with fruquintinib-induced hypertension in advanced G/GEJ adenocarcinoma patients treated with fruquintinib plus paclitaxel.
Methods
FRUTIGA was a randomized, double-blind, placebo-controlled phase 3 study. The treatment arm was given fruquintinib 4 mg orally, once daily for 3 weeks followed by 1 week off, plus paclitaxel 80 mg/m2 intravenously on days 1/8/15 per cycle. Post hoc analyses were conducted in the treatment arm.
Results
351 patients were randomized to fruquintinib plus paclitaxel treatment arm. Among these patients, 59 (16.8%) experienced fruquintinib-induced hypertension. 23 (6.6%) experienced grade 3 or more fruquintinib-induced hypertension. No patient permanently discontinued due to hypertension. These patients had a better clinical outcome than those with no occurrence of fruquintinib-induced hypertension, with higher objective response rates (ORR) of 57.6% (95% CI 44.1%-70.4%) versus 39.4% (95% CI 33.7%-45.2%) (p=0.0136). Progression-free survival (PFS) and overall survival (OS) were 8.08 months (95% CI 6.4-8.3) (p=0.0003) and 11.80 months (95% CI 9.3-16.2) (p=0.0157) in the fruquintinib-induced hypertension group, versus 4.63 months (95% CI 4.6-5.9) and 9.36 months (95% CI 8.4-10.4) in no fruquintinib-induced hypertension group, respectively.
Conclusions
Fruquintinib-induced hypertension was associated with higher ORR, longer PFS and OS in advanced G/GEJ adenocarcinoma patients. The fruquintinib-induced hypertension could potentially be predictive of clinical outcomes for pts with treatment with fruquintinib plus paclitaxel.
Clinical trial identification
NCT03223376.
Editorial acknowledgement
Legal entity responsible for the study
Hutchmed Limited.
Funding
The National Science and Technology Major Project (project no. 2019ZX09301012), the Science and Technology Commission of Shanghai Municipality (Science, Technology and Innovation Action Plan, project no. 17431900100) and Hutchmed Limited.
Disclosure
Q. Liu, S. Fan: Financial Interests, Personal, Full or part-time Employment: Hutchmed Limited. All other authors have declared no conflicts of interest.
Resources from the same session
1919P - Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Presenter: Luigi Cerbone
Session: Poster session 18
1918P - Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience
Presenter: Manal Elgendy
Session: Poster session 18
1917P - Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma
Presenter: Vilde Haakensen
Session: Poster session 18
1916P - Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study
Presenter: LUANA CALABRO
Session: Poster session 18
1915P - Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
Presenter: Matthew Ning
Session: Poster session 18
1914P - Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Presenter: Omar Abdel-Rahman
Session: Poster session 18
1913P - Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance
Presenter: Joyce Chan
Session: Poster session 18
1912P - AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
Presenter: Samaantha Bove
Session: Poster session 18
1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France
Presenter: Laurent Greillier
Session: Poster session 18